EpicentRx Announces Oral and Poster Presentations at the 2022 American Thoracic Society (ATS) Respiratory Innovation Summit

by EpicentRx | May 10, 2022 | 2022, Press Releases

TORREY PINES, Calif., May 10, 2022 — EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has...

Neuroendocrine Tumors Market to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – EpicentRx, Pfizer, Ignyta, Amgen, Progenics Pharma, Hutchison MediPharma, and Others

by EpicentRx | May 2, 2022 | Media

Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More

by EpicentRx | Apr 25, 2022 | Media

EpicentRx “BETA-PRIME” Phase 1 Study Progresses After Demonstrating Good Safety and Tolerability

by EpicentRx | Apr 21, 2022 | 2022, Press Releases

Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer TORREY PINES, Calif., April 21, 2022 — EpicentRx Inc., a leading-edge immunotherapy company using...

EpicentRx begins Phase I trial of paediatric CNS tumour treatment

by EpicentRx | Feb 25, 2022 | Media